A recent study published in Nature Biotechnology revealed the development of high-fidelity Cas13 variants with markedly reduced collateral effects by mutagenesis and demonstrated the feasibility of hfCas13 for efficient on-target RNA degradation with almost no collateral damage in mammalian cells and animals.
Click here for original story, High-fidelity Cas13 variants with minimal collateral RNA targeting
Source: Phys.org